Chimerix Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Chimerix hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.92
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05

Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Chimerix EPS misses by $0.01, beats on revenue

Nov 05

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von CMRX in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von CMRX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Chimerix Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von CMRX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (CMRX)	n/a
Untere 25 % des Marktes (US)	1.6%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (CMRX)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von CMRX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von CMRX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von CMRX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da CMRX keine Ausschüttungen gemeldet hat.

Chimerix Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Consensus revenue estimates fall by 36%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Price target decreased by 8.7% to US$7.00

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Consensus revenue estimates fall by 22%

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

Consensus revenue estimates decrease by 48%, EPS upgraded

New minor risk - Market cap size

Price target decreased by 8.3% to US$7.33

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought US$98k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Price target decreased to US$8.00

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Price target decreased to US$8.00

Chief Business Officer exercised options to buy US$111k worth of stock.

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Price target decreased to US$8.20

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus EPS estimates fall by 23%

Consensus estimates of losses per share improve by 44%

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Chimerix: Searching For Clarity

Forecast to breakeven in 2024

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Consensus revenue estimates fall to US$27.8m

Independent Director recently bought US$78k worth of stock

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Consensus forecasts updated

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Forecast to breakeven in 2024

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow

Consensus revenue estimates fall to US$43.6m

First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020)

Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019)

Revenue behind estimates

Analysts update estimates

Chimerix, Inc. Reports Topline Results from the First Cohort of Its Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study

New 90-day high: US$9.49

Chimerix, Inc. (NasdaqGM:CMRX) acquired Oncoceutics, Inc. from Spring Mountain Capital, LP and others for $68.3 million